GlassScriptPhysician profile
Karen E Canniff
NPI 1578086260
$6,588.82
in general payments reported to CMS, 2019-2025
23 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $932 · 2022: $1,188 · 2023: $1,724 · 2024: $1,712 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,250.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $672.07 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Pfizer INC. | $660.79 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.79 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $510.83 | 2021-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $429.60 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $328.34 | 2022-2025 | Repatha, Repatha |
| Abbott Laboratories | $288.40 | 2021-2025 | Mitraclip, Cardiomems |
| Kiniksa Pharmaceuticals, LTD. | $261.04 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $260.19 | 2022-2024 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $228.01 | 2024 | Arcalyst |
| Cvrx, INC. | $226.54 | 2023-2025 | Barostim Neo System |
| W. L. Gore & Associates, INC. | $138.24 | 2024 | Gore Cardioform Septal Occluder |
| Lexicon Pharmaceuticals, INC. | $137.29 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $134.73 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $122.04 | 2022-2024 | Cleviprex, Kengreal |
| Janssen Pharmaceuticals, INC | $87.42 | 2021-2023 | Xarelto |
| Bridgebio Pharma, INC. | $74.01 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $69.29 | 2023-2024 | Verquvo |
| Esperion Therapeutics, INC. | $67.65 | 2021-2024 | Nexletol |
| Cleerly, INC. | $50.33 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Abiomed | $30.74 | 2024 | Impella |
| Scpharmaceuticals INC. | $17.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Canniff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.